Pharmacoepigenetics of hypertension: genome-wide methylation analysis of responsiveness to four classes of antihypertensive drugs using a double-blind crossover study design
Open Access
- 25 February 2022
- journal article
- research article
- Published by Taylor & Francis in Epigenetics
- Vol. 17 (11) , 1432-1445
Abstract
Essential hypertension remains the leading risk factor of global disease burden, but its treatment goals are often not met. We investigated whether DNA methylation is associated with antihypertensive responses to a diuretic, a beta-blocker, a calcium channel blocker or an angiotensin receptor antagonist. In addition, since we previously showed an SNP at the transcription start site (TSS) of the catecholamine biosynthesis-related ACY3 gene to associate with blood pressure (BP) response to beta-blockers, we specifically analysed the association of methylation sites close to the ACY3 TSS with BP responses to beta-blockers. We conducted an epigenome-wide association study between leukocyte DNA methylation and BP responses to antihypertensive monotherapies in two hypertensive Finnish cohorts: the GENRES (https://clinicaltrials.gov/ct2/show/NCT03276598; amlodipine 5 mg, bisoprolol 5 mg, hydrochlorothiazide 25 mg, or losartan 50 mg daily) and the LIFE-Fin studies (https://clinicaltrials.gov/ct2/show/NCT00338260; atenolol 50 mg or losartan 50 mg daily). The monotherapy groups consisted of approximately 200 individuals each. We identified 64 methylation sites to suggestively associate (P < 1E-5) with either systolic or diastolic BP responses to a particular study drug in GENRES. These associations did not replicate in LIFE-Fin . Three methylation sites close to the ACY3 TSS were associated with systolic BP responses to bisoprolol in GENRES but not genome-wide significantly (P < 0.05). No robust associations between DNA methylation and BP responses to four different antihypertensive drugs were identified. However, the findings on the methylation sites close to the ACY3 TSS may support the role of ACY3 genetic and epigenetic variation in BP response to bisoprolol.Keywords
Funding Information
- Sigrid Juselius Foundation (20032019KK)
- the Finnish Foundation for Cardiovascular Research
- Sydäntutkimussäätiö (08042019KK)
This publication has 49 references indexed in Scilit:
- Enrichr: interactive and collaborative HTML5 gene list enrichment analysis toolBMC Bioinformatics, 2013
- Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarrayEpigenetics, 2013
- SWAN: Subset-quantile Within Array Normalization for Illumina Infinium HumanMethylation450 BeadChipsGenome Biology, 2012
- DNA methylation arrays as surrogate measures of cell mixture distributionBMC Bioinformatics, 2012
- Differential aminoacylase expression in neuroblastomaInternational Journal of Cancer, 2010
- Plasma Renin Activity Predicts Blood Pressure Responses to -Blocker and Thiazide Diuretic as Monotherapy and Add-On Therapy for HypertensionAmerican Journal of Hypertension, 2010
- Substitution of connexin40 with connexin45 prevents hyperreninemia and attenuates hypertensionKidney International, 2009
- Laboratory tests as predictors of the antihypertensive effects of amlodipine, bisoprolol, hydrochlorothiazide and losartan in men: results from the randomized, double-blind, crossover GENRES StudyJournal Of Hypertension, 2008
- Specificity of Aminoacylase III-Mediated Deacetylation of Mercapturic AcidsDrug Metabolism and Disposition, 2007
- Structural characterization, tissue distribution, and functional expression of murine aminoacylase IIIAmerican Journal of Physiology-Cell Physiology, 2004